search
Back to results

Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.

Primary Purpose

Hereditary Hemochromatosis, Hyperferritinemia

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Venipuncture
Sponsored by
Interregionale Blutspende SRK
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hereditary Hemochromatosis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age:18-75 years Body weight > 50 Kg Haemoglobin ≥ 135 g/l (males), ≥ 125 g/l (females) In subjects of the HH and non-HH group: ferritin values >500 ng/ml, which must have been measured in the last three months before the inclusion in the study (either at the Blood Donation service or elsewhere), not followed by a blood donation or a phlebotomy In subjects of the HH group: genetic test demonstrating the presence of p.C282Y homozygous or p.C282Y/p.H63D compound heterozygous HFE-gene mutation In subjects of the control group: ferritin values < 300 ng/ml (males) or < 200 ng/ml (females) Written informed consent to the participation in the study Exclusion Criteria: Inadequate vein access for whole blood collection Body weight < 50 kg Chronic viral infection (hepatitis B or C, HIV) Previous acute coronary heart disease Previous or current history of epilepsy Other severe conditions that could significantly increase the phlebotomy risk, based on individual medical evaluation No informed consent Pregnancy (according to the information on the standard blood donor questionnaire)

Sites / Locations

  • Blutspendedienst SRK beider Basel
  • Interregionale Blutspende SRK

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Other

Arm Label

Hereditary hemochromatosis

secondary hyperferritinemia

healthy blood donor with normal ferritin value.

Arm Description

Individual with ferritin >500 ng/mL and documented homozygous or compound heterozygous HFE-gen mutation.

Individual with ferritin >500 ng/mL, not fulfilling the criteria for hereditary hemochromatosis.

Healthy comparator.

Outcomes

Primary Outcome Measures

Hemolysis rate vs regulatory standards.
To verify that the hemolysis rate in % at the end of storage (day 42) of RBC from individuals with elevated ferritin is within the current accepted European standard of 0.8%.

Secondary Outcome Measures

Hemolysis hyperferritinemia vs controls end of storage.
Comparison of haemolysis rate in % at day 42 in RBC from individuals with elevated ferritin of any cause and those with normal ferritin levels.
Hemolysis hereditary hemochromatosis (HH) vs secondary hyperferritinemia entd of storage.
Comparisons of hemolysis rate in % at day 42 in RBC from individuals with HH and those with secondary hyperferritinemia.
Hemolysis hyperferritinemia vs controls day 1.
Comparisons of hemolysis rate in % at day 1 in RBC from individuals with hyperferritinemia and those with normal ferritin.

Full Information

First Posted
February 6, 2023
Last Updated
February 14, 2023
Sponsor
Interregionale Blutspende SRK
search

1. Study Identification

Unique Protocol Identification Number
NCT05742035
Brief Title
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
Official Title
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
January 18, 2023 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Interregionale Blutspende SRK

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Iron overload in hereditary hemochromatosis (HH) is treated by phlebotomy. It is unclear, if individuals with hyperferritinemia due to hereditary hemochromatosis or to secondary causes are suitable as blood donors. The study investigates hemolysis and several other quality parameters of red blood cell concentrates (RBC) obtained from 80 individual with ferritin >500 ng/mL - due to hereditary hemochromatosis or secondary - and 20 healthy blood donors as control.
Detailed Description
Iron overload in hereditary hemochromatosis is treated by phlebotomy. In Switzerland and in many other coutries, these individuals are not accepted for blood donation until ferritin values and phlebotomy intervals are in the normal range. Individual with secondary hyperferritinemia, e. g. related to metabolic syndrome, are accepted as blood donors according to their clinical situation. It is unclear if the quality of blood products issued from individuals with hyperferritinemia due to hereditary hemochromatosis or to secondary causes is comparable with the quality of those issued from healthy blood donors, and if their characteristics comply with the international standards. The study investigates the hemolysis rate and several other quality parameters in RBC obtained from 80 individual with ferritin >500 ng/mL - due to hereditary hemochromatosis or secondary - and 20 healthy blood donors as control. For this purpose, whole blood donations are manufactured according to the standard processes applied in the blood bank. Several standard quality parameters as well as biologic, rheologic, and oxydative stress-related variables are measured and compared, both with the current regulations and with those of the control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hereditary Hemochromatosis, Hyperferritinemia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective inclusion of individual and group allocation according to the collected clinical data and diagnoses.
Masking
InvestigatorOutcomes Assessor
Masking Description
Assessors of quality parameters don't know the diagnosis of the included participants
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hereditary hemochromatosis
Arm Type
Experimental
Arm Description
Individual with ferritin >500 ng/mL and documented homozygous or compound heterozygous HFE-gen mutation.
Arm Title
secondary hyperferritinemia
Arm Type
Experimental
Arm Description
Individual with ferritin >500 ng/mL, not fulfilling the criteria for hereditary hemochromatosis.
Arm Title
healthy blood donor with normal ferritin value.
Arm Type
Other
Arm Description
Healthy comparator.
Intervention Type
Procedure
Intervention Name(s)
Venipuncture
Intervention Description
Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
Primary Outcome Measure Information:
Title
Hemolysis rate vs regulatory standards.
Description
To verify that the hemolysis rate in % at the end of storage (day 42) of RBC from individuals with elevated ferritin is within the current accepted European standard of 0.8%.
Time Frame
After 42 days of storage
Secondary Outcome Measure Information:
Title
Hemolysis hyperferritinemia vs controls end of storage.
Description
Comparison of haemolysis rate in % at day 42 in RBC from individuals with elevated ferritin of any cause and those with normal ferritin levels.
Time Frame
After 42 days of storage
Title
Hemolysis hereditary hemochromatosis (HH) vs secondary hyperferritinemia entd of storage.
Description
Comparisons of hemolysis rate in % at day 42 in RBC from individuals with HH and those with secondary hyperferritinemia.
Time Frame
After 42 days of storage
Title
Hemolysis hyperferritinemia vs controls day 1.
Description
Comparisons of hemolysis rate in % at day 1 in RBC from individuals with hyperferritinemia and those with normal ferritin.
Time Frame
After 42 days of storage

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age:18-75 years Body weight > 50 Kg Haemoglobin ≥ 135 g/l (males), ≥ 125 g/l (females) In subjects of the HH and non-HH group: ferritin values >500 ng/ml, which must have been measured in the last three months before the inclusion in the study (either at the Blood Donation service or elsewhere), not followed by a blood donation or a phlebotomy In subjects of the HH group: genetic test demonstrating the presence of p.C282Y homozygous or p.C282Y/p.H63D compound heterozygous HFE-gene mutation In subjects of the control group: ferritin values < 300 ng/ml (males) or < 200 ng/ml (females) Written informed consent to the participation in the study Exclusion Criteria: Inadequate vein access for whole blood collection Body weight < 50 kg Chronic viral infection (hepatitis B or C, HIV) Previous acute coronary heart disease Previous or current history of epilepsy Other severe conditions that could significantly increase the phlebotomy risk, based on individual medical evaluation No informed consent Pregnancy (according to the information on the standard blood donor questionnaire)
Facility Information:
Facility Name
Blutspendedienst SRK beider Basel
City
Basel
Country
Switzerland
Facility Name
Interregionale Blutspende SRK
City
Berne
ZIP/Postal Code
3008
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.

We'll reach out to this number within 24 hrs